Andrew S. Cook - Concepedia

Author

Andrew S. Cook

Pfizer (United States)

Also Known As

A Cook, A. Cook, A. S. Cook, A.S. Cook, Amil N.T. Cook, Andrew Cook, Andrew S. Cook, Andrew S. Cook, Cook, A.S.

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Pfizer (United Kingdom)Imperial College London Northwestern University Genomics (United Kingdom)

About

Andrew S. Cook is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.4K
2	Natural Sciences	9	9	700
3	Engineering	2	2	205
4	Public Health	1	1	39
5	Applied Physics	1	1	77

Andrew S. Cook

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of glycogen synthase kinase-3 alleviates Tcf3 repression of the pluripotency network and increases embryonic stem cell resistance to differentiation Jason Wray, Tüzer Kalkan, Sandra Gómez‐López, Nature Cell Biology Embryonic Stem CellLineage PlasticityInduced Pluripotent Stem CellDevelopmental BiologyCell Regulation	2011	535
Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas Rishi G. Vaswani, Victor Gehling, Les A. Dakin, Journal of Medicinal Chemistry	2016	214
Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit Paul V. Fish, P. Filippakopoulos, Gerwyn Bish, Journal of Medicinal Chemistry Histone ModificationsPharmaceutical ScienceDrug TargetBioorganic ChemistryFragment-derived Hit	2012	195
Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds Constantin Cretu, Anant A. Agrawal, Andrew S. Cook, Molecular Cell Medicinal ChemistryMedicineNatural SciencesAnti-cancer AgentChemical Biology	2018	173
EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation William D. Bradley, Shilpi Arora, Jennifer Busby, Chemistry & Biology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyCancer Cell Biology	2014	148
Asymmetric Baylis–Hillman reactions: catalysis using a chiral pyrrolizidine base Anthony G. M. Barrett, Andrew S. Cook, Akio Kamimura Chemical Communications Enantiomeric ExcessEngineeringBiochemistryMethyl Vinyl KetonesNatural Sciences	1998	128
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib Qinhua Huang, Ted W. Johnson, Simon Bailey, Journal of Medicinal Chemistry Aminopyridine 8ETumor BiologyKinase DomainNovel TherapyMedicine	2014	115
A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced‐Fit Pocket Stabilized by a Cation–π Interaction Timothy P. C. Rooney, P. Filippakopoulos, O. Fedorov, Angewandte Chemie International Edition	2014	115
The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action Lorenzo I. Finci, Xiaofeng Zhang, Xiuliang Huang, Genes & Development	2018	109
Luminescence of rhenium(I) complexes with highly sterically hindered .alpha.-diimine ligands Arden P. Zipp, LouAnn Sacksteder, Julie Streich, Inorganic Chemistry Inorganic ChemistryEngineeringBiochemistryDonut IconNatural Sciences	1993	77

Page 1